Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Authors :: Cazzaniga M
Verusio C
Ciccarese M
Fumagalli A
Sartori D
Valerio MR
Airoldi M
Moretti G
Ficorella C
Arcangeli V
Diodati L
Zambelli A
Febbraro A
Generali D
Pistelli M
Garrone O
Musolino A
Vici P
Maur M
Mentuccia L
La Verde N
Bianchi G
Artale S
Blasi L
Piezzo M
Atzori F
Turletti A
Benedetto C
Cursano MC
Fabi A
Gebbia V
Schirone A
Palumbo R
Ferzi A
Frassoldati A
Scavelli C
Clivio L
Torri V
Source :: Oncotarget [Oncotarget] 2018 Nov 30; Vol. 9 (94), pp. 36720-36721. Date of Electronic Publication: 2018 Nov 30 (Print Publication: 2018).
Publication Year :: 2018
Abstract: [This corrects the article DOI: 10.18632/oncotarget.25874.].

Full Text Access

Tools